Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 + Tislelizumab +/- 5-FU vs Chemotherapy + Tislelizumab in First-line Esophageal Squamous Cell Carcinoma
NCT07554456Phase 3Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Biokin Pharmaceutical. Started Jun 2026; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07554456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07554456.